Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration...

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023 ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting - Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders - - CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation,...